- Previous Close
233.05 - Open
232.40 - Bid 206.00 x --
- Ask 207.20 x --
- Day's Range
202.55 - 233.15 - 52 Week Range
130.15 - 358.50 - Volume
144,310 - Avg. Volume
106,637 - Market Cap (intraday)
93.709B - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
25.42 - EPS (TTM)
8.13 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield 0.60 (0.26%)
- Ex-Dividend Date Sep 17, 2024
- 1y Target Est
299.33
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
marksanspharma.com1,141
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: MARKSANS.BO
View MorePerformance Overview: MARKSANS.BO
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MARKSANS.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MARKSANS.BO
View MoreValuation Measures
Market Cap
105.66B
Enterprise Value
100.82B
Trailing P/E
28.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.27
Price/Book (mrq)
4.63
Enterprise Value/Revenue
4.08
Enterprise Value/EBITDA
17.30
Financial Highlights
Profitability and Income Statement
Profit Margin
14.89%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
24.74B
Net Income Avi to Common (ttm)
3.68B
Diluted EPS (ttm)
8.13
Balance Sheet and Cash Flow
Total Cash (mrq)
6.72B
Total Debt/Equity (mrq)
8.60%
Levered Free Cash Flow (ttm)
--